News Releases

Jan 18, 2022
  Preliminary 2021 full-year pro forma net sales at high-end of $76-80 million guidance, representing approximately 55% growth from 2020 Year-end 2021 preliminary cash, cash equivalents, and investments of approximately $102 million 20+ million Medicaid lives in IL, TN, PA, OH, and CA have
Jan 03, 2022
CHICAGO --(BUSINESS WIRE)--Jan. 3, 2022-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) (“Xeris” or the “Company”), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on January

Request email alerts